IL163547A0 - Use of the axl receptor for diagnosis and treatment of renal disease - Google Patents

Use of the axl receptor for diagnosis and treatment of renal disease

Info

Publication number
IL163547A0
IL163547A0 IL16354703A IL16354703A IL163547A0 IL 163547 A0 IL163547 A0 IL 163547A0 IL 16354703 A IL16354703 A IL 16354703A IL 16354703 A IL16354703 A IL 16354703A IL 163547 A0 IL163547 A0 IL 163547A0
Authority
IL
Israel
Prior art keywords
diagnosis
treatment
renal disease
axl receptor
axl
Prior art date
Application number
IL16354703A
Other languages
English (en)
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of IL163547A0 publication Critical patent/IL163547A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16354703A 2002-02-12 2003-02-12 Use of the axl receptor for diagnosis and treatment of renal disease IL163547A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35637402P 2002-02-12 2002-02-12
PCT/US2003/004186 WO2003068983A1 (en) 2002-02-12 2003-02-12 Use of the axl receptor for diagnosis and treatment of renal disease

Publications (1)

Publication Number Publication Date
IL163547A0 true IL163547A0 (en) 2005-12-18

Family

ID=27734638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16354703A IL163547A0 (en) 2002-02-12 2003-02-12 Use of the axl receptor for diagnosis and treatment of renal disease

Country Status (7)

Country Link
US (3) US20030157573A1 (xx)
EP (1) EP1483400A4 (xx)
JP (1) JP2005517412A (xx)
CN (1) CN1646695A (xx)
AU (1) AU2003223172A1 (xx)
IL (1) IL163547A0 (xx)
WO (1) WO2003068983A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068983A1 (en) * 2002-02-12 2003-08-21 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
US8038996B2 (en) 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
TW200726845A (en) * 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2009005813A1 (en) * 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
KR101951410B1 (ko) 2010-01-22 2019-02-26 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-전이성 요법에서 ａｘｌ 신호전달의 저해
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
EP3076966A2 (en) * 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
MX2017005126A (es) * 2014-10-20 2017-09-15 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA3049444A1 (en) 2017-01-12 2018-07-19 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CN113215157B (zh) * 2021-05-20 2022-06-21 徐州医科大学 特异性靶向人AXL基因的sgRNA及其应用
CN113252911B (zh) * 2021-07-02 2021-12-10 珠海丽珠试剂股份有限公司 SARS-CoV-2中和抗体的检测试剂盒及其应用
KR20230080560A (ko) * 2021-11-30 2023-06-07 충남대학교산학협력단 Axl을 포함하는 지방간 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
EP0730646A1 (en) * 1993-11-23 1996-09-11 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
EP0739488A1 (en) * 1994-01-14 1996-10-30 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6236769B1 (en) * 1998-01-28 2001-05-22 Cognex Corporation Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
EP2325193A3 (en) * 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
WO2003068983A1 (en) * 2002-02-12 2003-08-21 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
EP2251434B1 (en) * 2003-01-16 2014-07-30 The Trustees of The University of Pennsylvania Compositions and methods for siRNA inhibition of ICAM-1

Also Published As

Publication number Publication date
EP1483400A1 (en) 2004-12-08
WO2003068983A9 (en) 2004-12-29
US20090042826A1 (en) 2009-02-12
EP1483400A4 (en) 2007-07-11
AU2003223172A1 (en) 2003-09-04
JP2005517412A (ja) 2005-06-16
US20090075923A1 (en) 2009-03-19
WO2003068983A1 (en) 2003-08-21
CN1646695A (zh) 2005-07-27
US20030157573A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
IL163547A0 (en) Use of the axl receptor for diagnosis and treatment of renal disease
EP1804661A4 (en) SYSTEM FOR INTEGRATED ILLNESS DIAGNOSIS AND TREATMENT
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1146725A1 (en) Thioflavin derivatives for use in the diagnosis of alzheimers disease
EP1581119A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS FOR INFLAMMATORY BOWEL DISEASE
EP1519683A4 (en) SOLID HYDROGEL COUPLING FOR IMAGING AND ULTRASONIC THERAPY
AU2003219689A8 (en) Method and system for risk-modulated diagnosis of disease
EP1687733A4 (en) SYSTEM AND PROCESS FOR ENABLING THE PROVISION OF HEALTH CARE
EP1817050A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
IL178815A0 (en) The treatment of respiratory disease
GB0410399D0 (en) The treatment of respiratory disease
GB0320238D0 (en) Treatment of disease
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
AU2003210266A8 (en) Treatment, diagnosis and imaging of disease
IL153183A0 (en) Agents for imaging and diagnostic methods using them
AU2003298719A8 (en) Treatment for sma disease
GB9909392D0 (en) Treatment, imaging and diagnosis of disease
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
GB2441078B (en) Implantable network biosensor and system for diagnosis and therapy
EP1767210A4 (en) MEDICAL USE OF PAEONIFLORIN
GB0209254D0 (en) Preparation for the relief of disease
AU2003297912A8 (en) Methods for screening compounds for use in the treatment of disease
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease
IL171925A0 (en) Use of endo-180 receptor for diagnosis and treatment ofdisease